A Study of HAIC Combined With Lenvatinib and Envolizumab in Potentially Resectable Hepatocellular Carcinoma
Conditions: Potentially Resectable Hepatocellular Carcinoma Interventions: Drug: FOLFOX-HAIC+Lenvatinib+Envolizumab Sponsors: Sun Yat-sen University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 22, 2023 Category: Research Source Type: clinical trials
Treatment of MB07133 Plus Sintilimab in Patients With Hepatocellular Carcinoma
Conditions: Safety Issues; Efficacy; MTD Interventions: Drug: Sintilimab 200mg+MB07133 600mg Sponsors: Xi ' an Xintong Pharmaceutical Research Co.,Ltd.; The First Hospital of Jilin University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 21, 2023 Category: Research Source Type: clinical trials
MB07133 for the Treatment of Patients With Unresectable Hepatocellular Carcinoma
Conditions: Safety Issues; Effect of Drug; Tolerance Interventions: Drug: MB07133 Sponsors: Xi ' an Xintong Pharmaceutical Research Co.,Ltd.; The First Hospital of Jilin University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 21, 2023 Category: Research Source Type: clinical trials
Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma Interventions: Drug: Lenvatinib Sponsors: Asan Medical Center; Eisai Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 18, 2023 Category: Research Source Type: clinical trials
A Prospective Study on the Application of Liquid Biopsy in the Surveillance of High-risk Population of HCC.
Conditions: Hepatocellular Carcinoma Interventions: Diagnostic Test: ultrasonic testing Sponsors: Tianjin Third Central Hospital; BGI, China Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 16, 2023 Category: Research Source Type: clinical trials
Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma Non-resectable Interventions: Drug: Atezolizumab; Drug: Bevacizumab; Radiation: Proton radiotherapy Sponsors: Chang Gung Memorial Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2023 Category: Research Source Type: clinical trials
Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma
Conditions: Primary Hepatocellular Carcinoma Interventions: Drug: Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)); Drug: camrelizumab for Injection Sponsors: CNBG-Virogin Biotech (Shanghai) Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 9, 2023 Category: Research Source Type: clinical trials
An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery
Conditions: Unresectable Hepatocellular Carcinoma Interventions: Drug: Atezolizumab; Drug: Bevacizumab; Drug: Durvalumab; Drug: Tremelimumab, Sponsors: Bayer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 6, 2023 Category: Research Source Type: clinical trials
Hepatitis B Virus Reactivation: a Cautionary Event After Liver Transplantation for Patients With Hepatocellular Carcinoma
Conditions: Liver Transplant; Complications Interventions: Diagnostic Test: Diagnosis of postoperative recurrence of liver cancer Sponsors: Zhejiang University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 2, 2023 Category: Research Source Type: clinical trials
TACE Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients With Hepatocellular Carcinoma (IDADOX)
Conditions: Hepatocellular Carcinoma; Liver Cancer Interventions: Procedure: IDA-TACE; Procedure: DOX-TACE Sponsors: Seoul National University Hospital; Guerbet Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 2, 2023 Category: Research Source Type: clinical trials
BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma Interventions: Drug: BC3402 injection; Drug: Durvalumab injection Sponsors: Biocity Biopharmaceutics Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 1, 2023 Category: Research Source Type: clinical trials
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
Conditions: Hepatocellular Carcinoma Interventions: Drug: Livmoniplimab; Drug: Budigalimab; Drug: Durvalumab; Drug: Atezolizumab; Drug: Bevacizumab; Drug: Tremelimumab Sponsors: AbbVie Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 31, 2023 Category: Research Source Type: clinical trials
Ultrasound Assessment of Sarcopenia in Patients With Chronic Liver Disease: the SARCOLIVER Study
Conditions: Liver Cirrhosis; Non-Alcoholic Fatty Liver Disease; Hepatocellular Carcinoma Interventions: Diagnostic Test: Handgrip strength test; Diagnostic Test: total body Dual Energy X-Ray Absorptiometry (DXA); Diagnostic Test: Muscle ultrasound Sponsors: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 26, 2023 Category: Research Source Type: clinical trials
ML Models for Predicting Postoperative Peritoneal Metastasis After Hepatocellular Carcinoma Rupture
Conditions: Peritoneal Metastasis Interventions: Other: Peritoneal Metastasis Sponsors: Chen Xiaoping Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 26, 2023 Category: Research Source Type: clinical trials
First Patient Treated in Multi-Center Pivotal Study of Eye90 microspheres in Hepatocellular Carcinoma
HALIFAX, NS, Oct. 25, 2023. ABK Biomedical, Inc., an innovative, medical device company dedicated to the research, development, and commercialization of advanced imageable embolic medical devices, today announced the first patient treated in its... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 25, 2023 Category: Pharmaceuticals Source Type: clinical trials
